Literature DB >> 3664104

Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia.

R Prudo1, H M Blum.   

Abstract

A sample of 100 schizophrenic patients admitted to London area psychiatric hospitals were examined as part of the International Pilot Study of Schizophrenia. Clinical and social outcome were variable. At 5-year follow-up, 49% had good symptomatic outcome and 42%, good social outcome. Poor social functioning at inclusion was predictive of poor symptomatic outcome. Illness history (IH), occupational functioning (OF), social relationship functioning (SRF), negative and non-specific symptoms (NNS) at initial evaluation, and their interaction with sex and race accounted for 32% of the 5-year symptomatic outcome variance (n = 84; F = 3.48; P less than 0.001). OF, SRF, housing status, NNS and their interaction with sex, race and age accounted for 47% of the social outcome variance (n = 62; F = 2.62; P less than 0.007).

Entities:  

Mesh:

Year:  1987        PMID: 3664104     DOI: 10.1192/bjp.150.3.345

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

1.  Diarrhoea during treatment with clozapine.

Authors:  M Launer
Journal:  BMJ       Date:  1992-11-07

2.  Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.

Authors:  Omer Saatcioglu; Murat Kalkan; Nurhan Fistikci; Sakire Erek; Kasim Candas Kilic
Journal:  Psychiatr Q       Date:  2016-06

3.  The role of estrogen in schizophrenia.

Authors:  M V Seeman
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

4.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

5.  Facts and meaning in psychiatry. An anthropological approach to the lifeworld of schizophrenics.

Authors:  E E Corin
Journal:  Cult Med Psychiatry       Date:  1990-06

Review 6.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

7.  Long-term follow-up of young Afro-Caribbean Britons and white Britons with a first admission diagnosis of schizophrenia.

Authors:  D McGovern; P Hemmings; R Cope; A Lowerson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1994-02       Impact factor: 4.328

8.  Predictability of rehospitalization for schizophrenia.

Authors:  J M Haro; W W Eaton; W B Bilker; P B Mortensen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 9.  Social skills programmes for schizophrenia.

Authors:  Muhammad Qutayba Almerie; Muhammad Okba Al Marhi; Muhammad Jawoosh; Mohamad Alsabbagh; Hosam E Matar; Nicola Maayan; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2015-06-09

10.  A follow-up study of high-functioning autistic children.

Authors:  P Szatmari; G Bartolucci; R Bremner; S Bond; S Rich
Journal:  J Autism Dev Disord       Date:  1989-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.